Drug evaluation: Degarelix - A potential new therapy for prostate cancer

IDrugs

Volumn 9, Issue 8, 2006, Pages 565-572

  Doehn, Christian ^a   Sommerauer, Martin ^a   Jocham, Dieter ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ADRENALIN; ANTIANDROGEN; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AZALINE B; BICALUTAMIDE; BUSERELIN; CETRORELIX; CORTICOSTEROID; CYPROTERONE ACETATE; DEGARELIX; ESTROGEN; FE 200486; FLUTAMIDE; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; LEUPRORELIN; NILUTAMIDE; PEPTIDE HORMONE ANTAGONIST; PLACEBO; TESTOSTERONE; TRIPTORELIN; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT DISORDER; BONE PAIN; CANCER INCIDENCE; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CASTRATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FATIGUE; FLUID THERAPY; GYNECOMASTIA; HISTAMINE RELEASE; HORMONAL THERAPY; HORMONE INHIBITION; HOT FLUSH; HUMAN; IMPOTENCE; KIDNEY FAILURE; MASTALGIA; METASTASIS; MUSCLE ATROPHY; NERVE ROOT COMPRESSION; NONHUMAN; ORCHIECTOMY; OXYGEN THERAPY; PATENT; PHARYNGITIS; PROSTATE CANCER; SPINAL CORD COMPRESSION; STRUCTURE ACTIVITY RELATION; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL; TREATMENT CONTRAINDICATION; UREMIA; URETER OBSTRUCTION; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; CLINICAL TRIALS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; OLIGOPEPTIDES; PROSTATIC NEOPLASMS;

EID: 33747623549     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. 45 Advances and trends in hormonal therapy for advanced prostate cancer. Debruyne FM, Dijkman GA EUR UROL 1995 28 3 177-188
2. 77 Clinical and experimental progression of a human prostate cancer, genetic alterations and change in hormone dependence. Oudard SM, Poirson-Bichat F, De Pinieux G, Bras-Goncalves R, Nemati F, Courty Y Lidereau R, Broqua P, Junien JL, Dutrillaux B, Poupon MF PROC AM ASSOC CANCER RES 2000 41 April 01-05 Abs 4248
3. 61 The natural history of early prostate cancer and the Impact of endocrine treatment. Adolfsson J EUR UROL 1999 36 Suppl 2 3-8
4. 563 Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Caubet J-F, Tosteson TD, Dong EW, Naylon EM, Writing GW, Emstoff MS, Ross SD UROLOGY 1997 49 1 71-78
5. 66 Development of GnRH antagonists for prostate cancer: New approaches to treatment. Cook T, Sheridan WP ONCOLOGIST 2000 5 2 162-168
6. 69 Estrogens in the treatment of prostate cancer. Cox RL, Crawford ED J UROL 1995 164 6 1991-1998
7. 88 Hormonal therapy in the management of prostate cancer: From Huggins to the present Garnick MB UROLOGY 1997 49 Suppl 3A 5-15
8. 11 Suppression of plasma gonadotropins by abarelix: A potent new LHRH antagonist. Molineaux J, Sluss P, Bree MP, Geller M, Sullivan LM, Garnick MB MOL UROL 1998 2 3 265-268
9. 15 Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Omstein DK, Oh J, Herschman JD, Andriole GL UROL CLIN NORTH AM 1998 25 4 591-601
10. 19 Hormone and antihormone withdrawal: Implications for the management of androgen-independent prostate cancer. Scher HI, Zhang ZF, Nanus D, Kelly WK UROLOGY 1996 47 1A Suppl 61-69
11. 17 GnRH antagonists: A now generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. Jiang G, Stalewski J, Galyean R, Dykert J, Schteingart C, Broqua P, Aebi A, Aubert ML, Semple G, Robson P, Akinsanya K, Haigh R J MED CHEM 2001 44 3 453-467
12. 52 Pharmacological profile of a new, patent and long-acting gonadotropin-releasing hormone antagonist: Degarelix. Broqua P, Riviere PJM, Conn PM, Rivier JE, Aubert ML, Junien JL J PHARMACOL EXP THER 2002 301 1 95-102
13. 85 Technology evaluation: Abarelix, Praecis Pharmaceuticals. Doehn C, Jocham D CURR OPIN MOL THER 2000 2 5 579-585
14. 59 A phase III, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, Fotheringham N, Campion M, Gamick MB J UROL 2002 167 4 1670-1674
15. 15 Is the flare phenomenon clinically significant? Bubley GJ UROLOGY 2001 58 2 Suppl 1 5-9
16. 16 A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. McLeod D, Zinner N, Tomera K, Gleason D, Fatheringham N, Campion M, Garnick MB UROLOGY 2001 58 5 756-761
17. 27 Ferring's degarelix shows promise in phase II prostate cancer trial. Ferring Pharmaceuticals A/S PRESS RELEASE 2004 October 05
18. 76 Ferring's degarelix effective in phase II prostate cancer trial. Ferring Pharmaceuticals A/S PRESS RELEASE 2005 March 19
19. 16 Development of GnRH antagonists for prostate cancer: New approaches to treatment. Cook T, Sheridan WP ONCOLOGIST 2000 5 2 162-168
20. 21 Population pharmacokinefic modeling of a subcutaneous depot for GnRH antagonist degarelix. Tomoe CW, Agerso H, Nielsen HA, Madsen H, Jonsson EN PHARM RES 2004 214 574-584
21. 22 Biodegradable PLGA microparticles for sustained release of a new GnRH antagonist: Part II. In. vivo performance. Schwach G, Oudry N, Giliberto JP, Broqua P, Luck M, Lindner H, Gurny R EUR J PHARM BIOPHARM 2004 67 3 441-446
22. 24 The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs. Agerso H, Koechling W, Knutsson M, Hjortkjaer R, Karlsson MO EUR J PHARM SCI 2003 20 3 335-340
23. 25 Biodegradable microparticles for sustained release of a new GnRH antagonist - Part 1: Screening commercial PLGA and formulation technologies. Schwach G, Oudry N, Delhomme S, Luck M, Lindner H, Gurny R EUR J PHARM BIOPHARM 2003 56 3 327-336
24. 83 Molecular biology of the androgen receptor: From molecular understanding to the clinic. Eder IE, Culig Z, Putz T, Nessler-Merardi C, Bartsch G, Klocker H EUR UROL 2001 40 3 241-251
25. 89 The natural history of prostate cancer. Kessler B, Albertsen P UROL CLIN NORTH AM 2003 30 2 219-226
26. 53 Schering ends license agreement for Praecis's prostate cancer drug. Praecis Pharmaceuticals Inc PRESS RELEASE 2005 September 29
27. 71 EAU guidelines on prostate cancer. Aus G, Abbou CC, Bolls M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F EUR UROL 2005 48 4 546-551
28. 72 Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Bajusz S, Kovacs M, Gazdag M, Bokser L, Karashima T, Csemus VJ, Janaky T, Guoth J, Schally AV PROC NATL ACAD SCI USA 1988 85 5 1637-1841
29. 78 Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative Intent for early nonmetastatic prostate cancer: 6.3-year median followup from the Scandinavian prostate cancer group study number 6. Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lumdmo P, Klarskov P, Tammela T, Tasdemir I, Morris T, Carroll K J UROL 2004 172 5 Pt 1 1871-1876
30. 79 Synthesis and biological activity of GnRH antagonists modified at position 3 with 3-(2-methoxy-6-pyridyl)-alanine. Samant MP, Miller C, Hong DJ, Koerber SC, Croston G, Rivier CL, Rivier JE J PEPT RES 2005 65 2 284-291
31. 80 Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median followup of 5.4 years. Wirth M, See WA, McLeod DG, Iversen P, Morris T, Caroll K J UROL 2004 172 5 Pt 1 1865-1870
32. 07 Ferring and Astellas enter a license agreement on degarelix for the treatment of prostate cancer in Japan. Ferring Pharmaceuticals A/S PRESS RELEASE 2006 February 06
33. 22 Iterative approach to the discovery of novel degarelix analogues: Substitutions at positions 3, 7, and 8. Part II. Samant MP, Gulyas J, Hong DJ, Croston G, Rivier C, Rivier J J MED CHEM 2005 48 15 4851-4860
34. 23 Stochastic differential equations In NONMEM: Implementation, application, and comparison with ordinary differential equations. Tornoe CW, Overgaard RV, Agerso H, Nielsen HA, Madsen H, Jonsson EN PHARM RES 2005 22 8 1247-1258
35. 26 Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: A comparison of the non-linear mixed-effects programs NONMEM and NLME. Tornoe CW, Agerso H, Nielsen HA, Madsen H, Jonsson EN J PHARMACOKINET PHARMACODYN 2005 31 6 441-461
36. 28 Degarelix - a phase II multicentre, randomized dose-escalating study testing a novel GnRH receptor blocker in prostate cancer patients. Tammela T, Iversen P, Johansson J, Persson B, Jensen J, Olesen T, Degarelix SG EUR UROL SUPPL 2005 4 3 228
37. 27 Degarelix, a novel GnRH blocker from Ferring, moves into phase III. Ferring Pharmaceuticals A/S PRESS RELEASE 2006 April 07
38. 74 Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III(1,2). Samant MP, Hong DJ, Croston G, Rivier C, Rvier J J MED CHEM 2006 49 12 3536-3543
39. 51 Cancer statistics, 2006. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ CA CANCER J CLIN 2006 56 2 108-130
40. 49 Degarelix: A novel GnRH receptor blocker tested in a multicenter, randomized dose-finding study in prostate cancer patilents. Persson BE, Hammonds J, Weston PMT, Vaughton K, Jensen JK, Eskerod O, Olesen TK INT SYMP GARH ANALOGUES CANCER HUM REPROD 2005 10-13
41. 10 Testosterone and PSA response in a one-year, multicentre, randomised study of degarelix, a gonadatrophin-releasing hormone (GnRH) receptor blocker, in patients with prostate cancer (CaP). Tombal B, de la Rosette J, Persson B, Jensen J, Olesen T ASCO PROSTATE CANCER SYMP 2006 Abs 187